News

Zacks Investment Research on MSN19d
CHMP Issues Positive Opinion for Label Expansion of BMY's Opdivo
Bristol Myers BMY announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has recommended approval of Opdivo (nivolumab) for another ...
Hosted on MSN19d
CHMP recommends oral peanut allergy immunotherapy treatment for toddlers
The European Medicines Agency’s (EMAs) Committee for Medicinal Products for Human Use (CHMP) has recommended extending the use of Stallergenes Greer’s oral immunotherapy, Palforzia (defatted ...
Morningstar23d
CHMP Recommends Against Approval of Eli Lilly's Kisunla Alzheimer's Drug
The European Medicines Agency's Committee for Medicinal Products for Human Use on Friday adopted a negative opinion on Kisunla, citing the risk of potentially fatal events due to amyloid-related ...
Yahoo Finance23d
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
PRINCETON, N.J., March 28, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
FiercePharma23d
Eli Lilly's Alzheimer's contender Kisunla gets thumbs-down from EU regulators over safety concerns
European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended against a marketing authorization for the drug’s use in early symptomatic Alzheimer’s disease.
Newsday23d
European committee says Lilly Alzheimer's drug shouldn't get marketing approval
The agency’s Committee for Medicinal Products for Human Use said Lilly can ask for a re-examination of its opinion. Lilly said Friday that it hopes discussions about the drug continue with the ...
JD Supra12d
Accord Receives Positive EMA Opinion for Two Denosumab Biosimilars
Accord received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for ...
Medscape23d
Alzheimer Drug Donanemab Gets No-Go From European Regulator
The agency's Committee for Medicinal Products for Human Use said that the benefits of the medicine were not sufficient to outweigh the risk of potentially fatal events. Donanemab is a monoclonal ...
Yahoo Finance19d
CHMP Issues Positive Opinion for Label Expansion of BMY's Opdivo
Bristol Myers BMY announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has recommended approval of Opdivo (nivolumab ...
KOB 423d
European committee says Lilly Alzheimer’s drug shouldn’t get marketing approval
The agency’s Committee for Medicinal Products for Human Use said Lilly can ask for a re-examination of its opinion. Lilly said Friday that it hopes discussions about the drug continue with the ...
WTHR22d
European committee says Lilly Alzheimer's drug shouldn't get marketing approval
The agency’s Committee for Medicinal Products for Human Use said Lilly can ask for a re-examination of its opinion. Lilly said Friday that it hopes discussions about the drug continue with the agency ...